Resumen
Objectives DAWN2 assessed the psychosocial impact of diabetes on persons with diabetes (PWDs), family members and healthcare professionals (HCPs) across 17 countries. This article reports on the Canadian cohort of PWDs. Methods PWDs completed online, validated self-report scales assessing quality of life (QOL), self-management, beliefs, social support and priorities for improving diabetes care. Analyses used unweighted data. Results Of 500 participants (80 type 1, 420 type 2) positive self-reported QOL was common (64.6%) and likely depression less common (12.8%). Diabetes distress, however, was identified by almost half of PWDs with type 1 diabetes, and one-quarter of PWDs with type 2 (47.5% vs. 25.7% type 2; p<0.001). Numerous life areas were negatively impacted, particularly finances, work and emotional well-being for those with type 1 diabetes (p<0.001 vs. type 2). Most PWDs reported support from family, friends and HCPs, but few reported being asked by HCPs how diabetes affected their lives. Most PWDs participated in (type 1, 90.0%; type 2, 85.7%) and valued (type 1, 84.7%; type 2, 78.1%) diabetes education. Few PWDs relied on community supports (type 1, 17.5%; type 2, 26.9%), and discrimination was not uncommon for those with type 1 (33.8% vs. 12.4% for type 2; p<0.001). Conclusions PWDs experience psychological challenges that should be addressed within diabetes management services.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 234-241 |
Número de páginas | 8 |
Publicación | Canadian Journal of Diabetes |
Volumen | 40 |
N.º | 3 |
DOI | |
Estado | Published - jun. 1 2016 |
Nota bibliográfica
Funding Information:The DAWN2 study is a global partnership of established organizations, including the International Diabetes Federation, the International Alliance of Patients' Organizations, the Steno Diabetes Center and Novo Nordisk. Novo Nordisk funded the DAWN2 study, which was overseen by the DAWN2 Study Group ( www.dawnstudy.com ). DAWN and DAWN2 are registered trademarks of Novo Nordisk. For more information, contact dawninfo@novonordisk.com . Editing support, funded by Novo Nordisk, was provided by Bioscript Medical, Macclesfield, Cheshire, United Kingdom.
Publisher Copyright:
© 2015 Canadian Diabetes Association
ASJC Scopus Subject Areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
PubMed: MeSH publication types
- Journal Article